A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients

Transplant Infectious Disease

Volumn 15, Issue 5, 2013, Pages 487-492

  Reid, G ^a   Huprikar, S ^b   Patel, G ^b   Razonable, R R ^c   Mossad, S ^d   Levi, M ^e   Gregg, K ^f   Shoham, S ^g   Humar, A ^h   Adams, W ^a   Kumar, D ^h  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF MICHIGAN   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Antiviral therapy; H1N1; HSCT; Viral infection

Indexed keywords

AMANTADINE; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OSELTAMIVIR; PERAMIVIR; RIMANTADINE; ZANAMIVIR; ANTIVIRUS AGENT;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIVIRAL THERAPY; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANADA; CLINICAL ARTICLE; CLINICAL EVALUATION; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HOSPITAL ADMISSION; HOSPITAL INFECTION; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; INFLUENZA A (H1N1); INTENSIVE CARE UNIT; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTE COUNT; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; RETROSPECTIVE STUDY; SYMPTOM; UNITED STATES; ADVERSE EFFECTS; CLINICAL TRIAL; COMPLICATION; CROSS INFECTION; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; INFLUENZA VIRUS A H1N1; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; MIDDLE AGED; PANDEMIC; RISK FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIVIRAL AGENTS; CROSS INFECTION; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMANS; INFECTION CONTROL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA, HUMAN; MALE; MIDDLE AGED; OSELTAMIVIR; PANDEMICS; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84884977509     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/tid.12116     Document Type: Article

References (30)

1. Nichols WG, Guthrie KA, Corey L, Boeckh M. Influenza infections after hematopoietic stem cell transplantation: risk factors, mortality, and the effect of antiviral therapy. Clin Infect Dis 2004; 39 (9): 1300-1306.
2. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer center. Medicine 2006; 85 (5): 278-287.
3. Boeckh M. The challenge of respiratory virus infections in hematopoietic cell transplant recipients. Br J Haemotol 2008; 143 (4): 455-467.
4. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplant for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11 (10): 781-796.
5. Khanna N, Steffen K, Studt JK, et al. Outcome of influenza infections in outpatients after allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2009; 11 (2): 100-105.
6. Ison MG, Hayden FG. Viral infections in immunocompromised patients: what's new with respiratory viruses? Curr Opin Infect Dis 2002; 15 (4): 355-367.
7. Ison MG. Respiratory syncytial virus and other respiratory viruses in the setting of bone marrow transplantation. Curr Opin Oncol 2009; 21 (2): 171-176.
8. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28 (5): 479-484.
9. Lee I, Barton T. Viral respiratory tract infections in transplant recipients. Drugs 2007; 67 (10): 1411-1427.
10. Monto AS. Epidemiology of viral respiratory infections. Am J Med 2002; 112 (6A): 4S-12S.
11. Jain S, Kamimoto L, Bramley AM, et al.; 2009 Pandemic Influenza A (H1N1) Hospitalizations Investigation Team. Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 2009; 361 (20): 1935-1944.
12. Redelman-Sidi G, Sepkowitz KA, Huang CK, et al. 2009 H1N1 influenza infection in cancer patients hematopoietic stem cell transplant recipients. J Infect 2010; 60 (4): 257-263.
13. Liu C, Schwartz B, Vallabhaneni S, et al. Pandemic (H1N1) 2009 infection in patients with hematologic malignancy. Emerg Infect Dis 2010; 16 (12): 1910-1917.
14. Suyani E, Aki Z, Guzel O, et al. H1N1 infection in a cohort of hematopoietic stem cell transplant recipients: prompt antiviral therapy might be life saving. Transpl Infect Dis 2011; 13 (2): 208-212.
15. Rihani R, Hayajneh W, Sultan I, et al. Infections with the 2009 H1N1 influenza virus among hematopoietic SCT recipients: a single center experience. Bone Marrow Transplant 2011; 46 (11): 1430-1436.
16. Choi SM, Boudreault AA, Xie H, et al. Differences in clinical outcomes after 2009 influenza A/H1N1 and seasonal influenza among hematopoietic cell transplant recipients. Blood 2011; 117 (19): 5050-5056.
17. Kharfan-Dabaja M, Velez A, Richards K, et al. Influenza A/pandemic 2009/H1N1in the setting of allogeneic hematopoietic cell transplantation: a potentially catastrophic problem in a vulnerable population. Int J Hematol 2010; 91 (1): 124-127.
18. Espinsoa-Aguilar L, Green J, Forrest GN, et al. Novel H1N1 influenza in hematopoietic stem cell transplantation recipients: two centers' experiences. Biol Blood Marrow Transplant 2011; 17 (4): 566-573.
19. Ljungman P, De la Camara R, Perez-Bercoff L, et al. Outcome of pandemic H1N1 infections in hematopoietic stem cell transplant recipients. Haemotologica 2011; 96 (8): 1231-1235.
20. Tramontana AR, George B, Hurt AC, et al. Oseltamivir resistance in adult oncology and hematology patients infected with pandemic (H1N1) 2009 virus, Australia. Emerg Infect Dis 2010; 16 (7): 1068-1075.
21. Mohty B, Thomas Y, Vukecevic M, et al. Clinical features and outcome of 2009-influenza H1N1 after allogeneic hematopoietic stem cell transplant. Bone Marrow Transplant 2012; 47 (2): 236-242.
22. Protheroe RE, Kirkland KE, Pearce RM, et al. Clinical features and outcome of 2009 H1N1 influenza infection in allo-SCT patients: a British Society of Blood and Marrow Transplantation Study. Bone Marrow Transplant 2012; 47 (1): 88-94.
23. Iloka F, Sada R, Maesako Y, et al. Outbreak of pandemic 2009 influenza A/H1N1 infection in the hematology ward: fatal clinical outcome of hematopoietic stem cell transplant recipients and emergence of the H275Y neuraminidase mutation. Int J Hematol 2012; 96: 365-369.
24. George B, Ferguson P, Kerridge I, et al. The clinical impact of infection with swine flu (H1N109) strain of influenza virus in hematopoietic stem cell transplant recipients. Biol Blood Marrow Transplant 2011; 17: 147-153.
25. Ellington SR, Hartman LK, Acosta M, et al. Pandemic 2009 influenza A (H1N1) in 71 critically ill pregnant women in California. Am J Obst Gynecol 2011; 6 (Suppl 1): S21-S30.
26. Lee N, Chan PKS, Kin WC, et al. Factors associated with early hospital discharge of adult influenza patients. Antivir Therapy 2007; 12 (4): 501-508.
27. CDC Update: influenza activity - United States, August 30, 2009 - January 9, 2010. MMWR Morb Mortal Wkly Rep 2010; 59 (2): 38-43.
28. Talbird SE, Brogan AJ, Winiarsh AP, Sander B. Cost Effectiveness of treating influenza-like illness with oseltamivir in the United States. Am J Health Syst Pharm 2009; 66 (5): 469-480.
29. Kumar D, Morris MI, Kotton CN, et al. Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant 2010; 10 (1): 18-25.
30. Zaia J, Baden L, Boekh MJ, et al. Viral disease prevention after hematopoietic cell transplantation. Bone Marrow Transplant, 2009; 44: 471-481.